Literature DB >> 2572974

Inhibition of 3H-noradrenaline accumulation by dopexamine hydrochloride in the isolated aorta of the rabbit.

O A Nedergaard1.   

Abstract

The aim of the present work was to study the ability of dopexamine hydrochloride to interfere with the neuronal and extraneuronal uptake mechanisms by investigating the effect of dopexamine hydrochloride on 3H-noradrenaline accumulation by rabbit isolated aorta. Dopexamine hydrochloride (3 x 10(-9) - 10(-5) mol/l) reduced the accumulation of tritium by aorta incubated with 3H-noradrenaline (10(-8) mol/l). The effect of dopexamine was compared to cocaine, dopamine, dobutamine, ADTN [(+/-)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene], ouabain and isoprenaline. Dopexamine hydrochloride (3 x 10(-9)-10(-7) mol/l) caused the same degree of inhibition irrespective of whether corticosterone (4 x 10(-5) mol/l) was present or not. The order of inhibitory potency was: desipramine greater than dopexamine hydrochloride greater than dopamine greater than ADTN greater than or equal to cocaine greater than dobutamine greater than ouabain greater than isoprenaline. In the presence of desipramine (10(-6) mol/l), corticosterone (10(-6)-10(-4) mol/l), but not dopexamine hydrochloride (10(-6) - 10(-4) mol/l), reduced the 3H-accumulation. It is concluded that dopexamine hydrochloride is a potent inhibitor of uptake-1 in rabbit isolated aorta. Dopexamine hydrochloride has no affinity for the uptake-2 mechanism in this tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572974     DOI: 10.1007/BF00168509

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  13 in total

1.  Rudolf Buchheim lecture. The metabolizing systems involved in the inactivation of catecholamines.

Authors:  U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-03       Impact factor: 3.000

2.  A kinetic analysis of drugs that inhibit the adrenergic neuronal membrane amine pump.

Authors:  F Berti; P A Shore
Journal:  Biochem Pharmacol       Date:  1967-11       Impact factor: 5.858

3.  Inhibition of noradrenaline uptake 2 in the isolated rat heart by steroids, clonidine and methoxylated phenylethylamines.

Authors:  P J Salt
Journal:  Eur J Pharmacol       Date:  1972-12       Impact factor: 4.432

4.  Molecular features affecting the potency of tricyclic antidepressants and structurally related compounds as inhibitors of the uptake of tritiated norepinephrine by rabbit aortic strips.

Authors:  R A Maxwell; P D Keenan; E Chaplin; B Roth; S B Eckhardt
Journal:  J Pharmacol Exp Ther       Date:  1969-04       Impact factor: 4.030

5.  Modulation by the muscarinic agonist McN-A-343 of noradrenaline release from vascular sympathetic neurones.

Authors:  O A Nedergaard
Journal:  J Cardiovasc Pharmacol       Date:  1980 Sep-Oct       Impact factor: 3.105

6.  Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.

Authors:  R A Brown; J Dixon; J B Farmer; J C Hall; R G Humphries; F Ince; S E O'Connor; W T Simpson; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

7.  Inhibition of catecholamine Uptake-2 by steroids in the isolated rat heart.

Authors:  L L Iversen; P J Salt
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

8.  Inhibition of Uptake1 by dopexamine hydrochloride in vitro.

Authors:  P D Mitchell; G W Smith; E Wells; P A West
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

9.  The effects of dopexamine on the cardiovascular system of the dog.

Authors:  R A Brown; J B Farmer; J C Hall; R G Humphries; S E O'Connor; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

10.  Evaluation of mechanisms controlling the release and inactivation of the adrenergic transmitter in the rabbit portal vein and vas deferens.

Authors:  J Hughes
Journal:  Br J Pharmacol       Date:  1972-03       Impact factor: 8.739

View more
  2 in total

1.  Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study.

Authors:  H Asanoi; S Sasayama; T Sakurai; J D Lee; M Kinoshita; T Ishimura; J Yoshikawa; K Mitsudo; H Sato; S Morioka
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.